Heparan sulfate proteoglycans and their modification as promising anticancer targets in hepatocellular carcinoma (Review)
- Authors:
- Mohammed A. Alshehri
- Moath M. Alshehri
- Naif N. Albalawi
- Moshari A. Al‑Ghamdi
- Mohammed M.H. Al‑Gayyar
-
Affiliations: PharmD Program, Faculty of Pharmacy, University of Tabuk, Tabuk 71491, Saudi Arabia - Published online on: January 4, 2021 https://doi.org/10.3892/ol.2021.12434
- Article Number: 173
-
Copyright: © Alshehri et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
|
Balkan E, Bilici M, Gundogdu B, Aksungur N, Kara A, Yasar E, Dogan H and Ozturk G: ERCC2 Lys751Gln rs13181 and XRCC2 Arg188His rs3218536 gene polymorphisms contribute to subsceptibility of colon, gastric, HCC, lung and prostate cancer. J BUON. 25:574–581. 2020.PubMed/NCBI | |
|
Lv Y, Xu A, Wang N, Mu K, Wang Z, Zhao L, Huang Y, Peng L, Xiang K, Hu D and Qi J: Retrospective study of TACE in the treatment of lobaplatin-induced thrombocytopenia in primary hepatocellular carcinoma. J BUON. 24:2385–2393. 2019.PubMed/NCBI | |
|
Nazmy EA, El-Khouly OA, Zaki MMA, MM A, Elsherbiny NM, Said E, Al-Gayyar MMH and Salem HA: Targeting p53/TRAIL/caspase-8 signaling by adiponectin reverses thioacetamide-induced hepatocellular carcinoma in rats. Environ Toxicol Pharmacol. 72:1032402019. View Article : Google Scholar : PubMed/NCBI | |
|
Sergio A, Cristofori C, Cardin R, Pivetta G, Ragazzi R, Baldan A, Girardi L, Cillo U, Burra P, Giacomin A and Farinati F: Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): The role of angiogenesis and invasiveness. Am J Gastroenterol. 103:914–921. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Xia Y, Zhang J and Ni X: Diagnsosis, treatment and prognosis of hepatocellualr carcinoma with inferior vena cava/right atrium tumor thrombus. Oncol Lett. 20:1012020. View Article : Google Scholar : PubMed/NCBI | |
|
Zeng Z, Yang B and Liao ZY: Current progress and prospect of immune checkpoint inhipitros in hepatocellualr carcinoma. Oncol Lett. 2:452020. | |
|
Iozzo RV: Heparan sulfate proteoglycans: Intricate molecules with intriguing functions. J Clin Invest. 108:165–167. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Kumar AV, Katakam SK, Urbanowitz AK and Gotte M: Heparan sulphate as a regulator of leukocyte recruitment in inflammation. Curr Protein Pept Sci. 16:77–86. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Christianson HC and Belting M: Heparan sulfate proteoglycan as a cell-surface endocytosis receptor. Matrix Biol. 35:51–55. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Rosen SD and Lemjabbar-Alaoui H: Sulf-2: An extracellular modulator of cell signaling and a cancer target candidate. Expert Opin Ther Targets. 14:935–949. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Bishop JR, Schuksz M and Esko JD: Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature. 446:1030–1037. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Poulain FE and Yost HJ: Heparan sulfate proteoglycans: A sugar code for vertebrate development? Development. 142:3456–3467. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Häcker U, Nybakken K and Perrimon N: Heparan sulphate proteoglycans: The sweet side of development. Nat Rev Mol Cell Biol. 6:530–541. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Lindahl U and Kjellén L: Pathophysiology of heparan sulphate: Many diseases, few drugs. J Intern Med. 273:555–571. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Tayel A, Abd El Galil KH, Ebrahim MA, Ibrahim AS, El-Gayar AM and Al-Gayyar MM: Suramin inhibits hepatic tissue damage in hepatocellular carcinoma through deactivation of heparanase enzyme. Eur J Pharmacol. 728:151–160. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Toyoshima M and Nakajima M: Human heparanase. Purification, characterization, cloning, and expression. J Biol Chem. 274:24153–24160. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Dong S and Wu XZ: Heparanase and hepatocellular carcinoma: Promoter or inhibitor? World J Gastroenterol. 16:306–311. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Yabluchanskiy A, Ma Y, Iyer RP, Hall ME and Lindsey ML: Matrix metalloproteinase-9: Many shades of function in cardiovascular disease. Physiology (Bethesda). 28:391–403. 2013.PubMed/NCBI | |
|
Powell WC and Matrisian LM: Complex roles of matrix metalloproteinases in tumor progression. Curr Top Microbiol Immunol. 213:1–21. 1996.PubMed/NCBI | |
|
Gonçalves JL, Roma EH, Gomes-Santos AC, Aguilar EC, Cisalpino D, Fernandes LR, Vieira AT, Oliveira DR, Cardoso VN, Teixeira MM and Alvarez-Leite JI: Pro-inflammatory effects of the mushroom Agaricus blazei and its consequences on atherosclerosis development. Eur J Nutr. 51:927–937. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Rowsell S, Hawtin P, Minshull CA, Jepson H, Brockbank SM, Barratt DG, Slater AM, McPheat WL, Waterson D, Henney AM and Pauptit RA: Crystal structure of human MMP9 in complex with a reverse hydroxamate inhibitor. J Mol Biol. 319:173–181. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Hadler-Olsen E, Winberg JO and Uhlin-Hansen L: Matrix metalloproteinases in cancer: Their value as diagnostic and prognostic markers and therapeutic targets. Tumour Biol. 34:2041–2051. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Deryugina EI and Quigley JP: Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 25:9–34. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Tassi E, McDonnell K, Gibby KA, Tilan JU, Kim SE, Kodack DP, Schmidt MO, Sharif GM, Wilcox CS, Welch WJ, et al: Impact of fibroblast growth factor-binding protein-1 expression on angiogenesis and wound healing. Am J Pathol. 179:2220–2232. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Lambaerts K, Wilcox-Adelman SA and Zimmermann P: The signaling mechanisms of syndecan heparan sulfate proteoglycans. Curr Opin Cell Biol. 21:662–669. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Vlodavsky I, Ilan N, Naggi A and Casu B: Heparanase: Structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate. Curr Pharm Des. 13:2057–2073. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
McKenzie EA: Heparanase: A target for drug discovery in cancer and inflammation. Br J Pharmacol. 151:1–14. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Ilan N, Elkin M and Vlodavsky I: Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol. 38:2018–2039. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Ferro V, Hammond E and Fairweather JK: The development of inhibitors of heparanase, a key enzyme involved in tumour metastasis, angiogenesis and inflammation. Mini Rev Med Chem. 4:693–702. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Morimoto-Tomita M, Uchimura K, Werb Z, Hemmerich S and Rosen SD: Cloning and characterization of two extracellular heparin-degrading endosulfatases in mice and humans. J Biol Chem. 277:49175–49185. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Yang XP, Liu L, Wang P and Ma SL: Human sulfatase-1 improves the effectiveness of cytosine deaminase suicide gene therapy with 5-fluorocytosine treatment on hepatocellular carcinoma cell line HepG2 in vitro and in vivo. Chin Med J (Engl). 128:1384–1390. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Bret C, Moreaux J, Schved JF, Hose D and Klein B: SULFs in human neoplasia: Implication as progression and prognosis factors. J Transl Med. 9:722011. View Article : Google Scholar : PubMed/NCBI | |
|
Zaghloul RA, Al-Gayyar MM, El-Shishtawy MM and Ebrahim MA: Cytotoxic effects of antiglypican-3 against HepG2 cell lines. J App Pharm Sci. 3:31–35. 2013. | |
|
Zaghloul RA, El-Shishtawy MM, El Galil KH, Ebrahim MA, Metwaly AA and Al-Gayyar MM: Evaluation of antiglypican-3 therapy as a promising target for amelioration of hepatic tissue damage in hepatocellular carcinoma. Eur J Pharmacol. 746:353–362. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Al-Gayyar MM, Abbas A and Hamdan AM: Chemopreventive and hepatoprotective roles of adiponectin (SULF2 inhibitor) in hepatocelluar carcinoma. Biol Chem. 397:257–267. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Zheng X, Gai X, Han S, Moser CD, Hu C, Shire AM, Floyd RA and Roberts LR: The human sulfatase 2 inhibitor 2,4-disulfonylphenyl-tert-butylnitrone (OKN-007) has an antitumor effect in hepatocellular carcinoma mediated via suppression of TGFB1/SMAD2 and Hedgehog/GLI1 signaling. Genes Chromosomes Cancer. 52:225–236. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Stepp MA, Pal-Ghosh S, Tadvalkar G and Pajoohesh-Ganji A: Syndecan-1 and its expanding list of contacts. Adv Wound Care (New Rochelle). 4:235–249. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Baghy K, Tátrai P, Regős E and Kovalszky I: Proteoglycans in liver cancer. World J Gastroenterol. 22:379–393. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Götte M, Kersting C, Radke I, Kiesel L and Wülfing P: An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ. Breast Cancer Res. 9:R82007. View Article : Google Scholar : PubMed/NCBI | |
|
Metwaly HA, Al-Gayyar MM, Eletreby S, Ebrahim MA and El-Shishtawy MM: Relevance of serum levels of interleukin-6 and syndecan-1 in patients with hepatocellular carcinoma. Sci Pharm. 80:179–188. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Schulze D, Plohmann P, Höbel S and Aigner A: Anti-tumor effects of fibroblast growth factor-binding protein (FGF-BP) knockdown in colon carcinoma. Mol Cancer. 10:1442011. View Article : Google Scholar : PubMed/NCBI | |
|
Gao B, Li S, Tan Z, Ma L and Liu J: ACTG1 and TLR3 are biomarkers for alcohol-associated hepatocellular carcinoma. Oncol Lett. 17:1714–1722. 2019.PubMed/NCBI | |
|
Metwaly HA, El-Gayar AM and El-Shishtawy MM: Inhibition of the signaling pathway of syndecan-1 by synstatin: A promising anti-integrin inhibitor of angiogenesis and proliferation in HCC in rats. Arch Biochem Biophys. 652:50–58. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Aggio A, Grassi D, Onori E, D'Alessandro A, Masedu F, Valenti M and Ferri C: Endothelium/nitric oxide mechanism mediates vasorelaxation and counteracts vasoconstriction induced by low concentration of flavanols. Eur J Nutr. 52:263–272. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Jeon Y, Jang ES, Choi YS, Kim JW and Jeong SH: Glypican-3 level assessed by the enzyme-linked immunosorbent assay is inferior to alpha-fetoprotein level for hepatocellular carcinoma diagnosis. Clin Mol Hepatol. 22:359–365. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Stigliano I, Puricelli L, Filmus J, Sogayar MC, Bal de Kier Joffé E and Peters MG: Glypican-3 regulates migration, adhesion and actin cytoskeleton organization in mammary tumor cells through Wnt signaling modulation. Breast Cancer Res Treat. 114:251–262. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Cheng W, Tseng CJ, Lin TT, Cheng I, Pan HW, Hsu HC and Lee YM: Glypican-3-mediated oncogenesis involves the Insulin-like growth factor-signaling pathway. Carcinogenesis. 29:1319–1326. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Ho M: Advances in liver cancer antibody therapies: A focus on glypican-3 and mesothelin. BioDrugs. 25:275–284. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Nakano K, Ishiguro T, Konishi H, Tanaka M, Sugimoto M, Sugo I, Igawa T, Tsunoda H, Kinoshita Y, Habu K, et al: Generation of a humanized anti-glypican 3 antibody by CDR grafting and stability optimization. Anticancer Drugs. 21:907–916. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Sun CK, Chua MS, He J and So SK: Suppression of glypican 3 inhibits growth of hepatocellular carcinoma cells through up-regulation of TGF-β2. Neoplasia. 13:735–747. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Miura M, Fujinami N, Shimizu Y, Mizuno S, Saito K, Suzuki T, Konishi M, Takahashi S, Gotohda N, Suto K, et al: Usefulness of plasma full-length glypican-3 as a predictive marker of hepatocellular carcinoma recurrence after radial surgery. Oncol Lett. 19:2657–2666. 2020.PubMed/NCBI | |
|
Elewa MA, Al-Gayyar MM, Schaalan MF, Abd El Galil KH, Ebrahim MA and El-Shishtawy MM: Hepatoprotective and anti-tumor effects of targeting MMP-9 in hepatocellular carcinoma and its relation to vascular invasion markers. Clin Exp Metastasis. 32:479–493. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Jayo A and Parsons M: Fascin: A key regulator of cytoskeletal dynamics. Int J Biochem Cell Biol. 42:1614–1617. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Huang X, Ji J, Xue H, Zhang F, Han X, Cai Y, Zhang J and Ji G: Fascin and cortactin expression is correlated with a poor prognosis in hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 24:633–639. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Oh SY, Kim YB, Suh KW, Paek OJ and Moon HY: Prognostic impact of fascin-1 expression is more significant in advanced colorectal cancer. J Surg Res. 172:102–108. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Hayashi Y, Osanai M and Lee GH: Fascin-1 expression correlates with repression of E-cadherin expression in hepatocellular carcinoma cells and augments their invasiveness in combination with matrix metalloproteinases. Cancer Sci. 102:1228–1235. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Lai JP, Thompson JR, Sandhu DS and Roberts LR: Heparin-degrading sulfatases in hepatocellular carcinoma: Roles in pathogenesis and therapy targets. Future Oncol. 4:803–814. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Abdel-Hamid NM: Premalignant variations in extracellular matrix composition in chemically induced hepatocellular carcinoma in rats. J Membr Biol. 230:155–162. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
de los Reyes GC, Koda RT and Lien EJ: Glucosamine and chondroitin sulfates in the treatment of osteoarthritis: A survey. Prog Drug Res. 55:81–103. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang L, Liu WS, Han BQ, Peng YF and Wang DF: Antitumor activities of D-glucosamine and its derivatives. J Zhejiang Univ Sci B. 7:608–614. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Tan HY, Eskandari R, Shen D, Zhu Y, Liu TW, Willems LI, Alteen MG, Madden Z and Vocadlo DJ: Direct one-step fluorescent labeling of O-GlcNAc-modified proteins in live cells using metabolic intermediates. J Am Chem Soc. 140:15300–15308. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Tayel A, Ebrahim MA, Ibrahim AS, El-Gayar AM and Al-Gayyar MM: Cytotoxic effects of suramin against HepG2 cells through activation of intrinsic apoptotic pathway. J BUON. 19:1048–1054. 2014.PubMed/NCBI | |
|
Al-Gayyar MMH, Ebrahim MA and Shams MEE: Measuring serum levels of glycosaminoglycans for prediction and using viscum fraxini-2 for treatment of patients with hepatocellular carcinoma. J Pharm Res. 7:571–575. 2013. | |
|
Bezabeh T, Ijare OB, Albiin N, Arnelo U, Lindberg B and Smith IC: Detection and quantification of D-glucuronic acid in human bile using 1H NMR spectroscopy: Relevance to the diagnosis of pancreatic cancer. MAGMA. 22:267–275. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Attallah AM, Toson el-SA, El-Waseef AM, Abo-Seif MA, Omran MM and Shiha GE: Discriminant function based on hyaluronic acid and its degrading enzymes and degradation products for differentiating cirrhotic from non-cirrhotic liver diseased patients in chronic HCV infection. Clin Chim Acta. 369:66–72. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Aruffo A, Stamenkovic I, Melnick M, Underhill CB and Seed B: CD44 is the principal cell surface receptor for hyaluronate. Cell. 61:1303–1313. 1990. View Article : Google Scholar : PubMed/NCBI | |
|
Varki NM and Varki A: Diversity in cell surface sialic acid presentations: Implications for biology and disease. Lab Invest. 87:851–857. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Arif S, Najeeb-ul-Haq, Hanif R, Khan AS, Jamil-ur-Rehman and Mufti TA: Variations of serum sialic acid level in liver cirrhosis. J Ayub Med Coll Abbottabad. 17:54–57. 2005. | |
|
Liu J, Wen X, Liu B, Zhang Q, Zhang J, Miao H and Zhu R: Diosmetin inhibits the metastasis of hepatocellular carcinoma cells by downregulating the expression levels of MMP-2 and MMP-9. Mol Med Rep. 13:2401–2408. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Tomizawa M, Shinozaki F, Motoyoshi Y, Sugiyama T, Yamamoto S and Ishige N: Niclosamide suppresses migration of hepatocellular carcinoma cells and downregulates matrix metalloproteinase-9 expression. Oncol Lett. 10:3515–3518. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Z, Dou C, Jia Y, Li Q, Zheng X, Yao Y, Liu Q and Song T: RIG-I suppresses the migration and invasion of hepatocellular carcinoma cells by regulating MMP9. Int J Oncol. 46:1710–1720. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Chen X, Bo L, Zhao X and Chen Q: MicroRNA-133a inhibits cell proliferation, colony formation ability, migration and invasion by targeting matrix metallopeptidase 9 in hepatocellular carcinoma. Mol Med Rep. 11:3900–3907. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Xu L, Wang T, Meng WY, Wei J, Ma JL, Shi M and Wang YG: Salinomycin inhibits hepatocellular carcinoma cell invasion and migration through JNK/JunD pathway-mediated MMP9 expression. Oncol Rep. 33:1057–1063. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Hsieh MJ, Lin CW, Yang SF, Chen MK and Chiou HL: Glabridin inhibits migration and invasion by transcriptional inhibition of matrix metalloproteinase 9 through modulation of NF-κB and AP-1 activity in human liver cancer cells. Br J Pharmacol. 171:3037–3050. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Yuxian X, Feng T, Ren L and Zhengcai L: Tanshinone II-A inhibits invasion and metastasis of human hepatocellular carcinoma cells in vitro and in vivo. Tumori. 95:789–795. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Darweish MM, Abbas A, Ebrahim MA and Al-Gayyar MM: Chemopreventive and hepatoprotective effects of Epigallocatechin-gallate against hepatocellular carcinoma: Role of heparan sulfate proteoglycans pathway. J Pharm Pharmacol. 66:1032–1045. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Chen XP, Luo JS, Tian Y, Nie CL, Cui W and Zhang WD: Downregulation of heparanase expression results in suppression of invasion, migration, and adhesion abilities of hepatocellular carcinoma cells. Biomed Res Int. 2015:2419832015. View Article : Google Scholar : PubMed/NCBI | |
|
Chen Z, Zhu L, Li X, Tian H, Fang Y, Liu H, Li S, Li L, Yue W and Li W: Down-regulation of heparanase leads to the inhibition of invasion and proliferation of A549 cells in vitro and in vivo. Acta Biochim Biophys Sin (Shanghai). 45:188–193. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Liu CJ, Chang J, Lee PH, Lin DY, Wu CC, Jeng LB, Lin YJ, Mok KT, Lee WC, Yeh HZ, et al: Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence. World J Gastroenterol. 20:11384–11393. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Liu CJ, Lee PH, Lin DY, Wu CC, Jeng LB, Lin PW, Mok KT, Lee WC, Yeh HZ, Ho MC, et al: Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage. J Hepatol. 50:958–968. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Alyoussef A and Al-Gayyar MMH: Cytotoxic and partial hepatoprotective activity of sodium ascorbate against hepatocellular carcinoma through inhibition of sulfatase-2 in vivo and in vitro. Biomed Pharmacother. 103:362–372. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Chen G, Nakamura I, Dhanasekaran R, Iguchi E, Tolosa EJ, Romecin PA, Vera RE, Almada LL, Miamen AG, Chaiteerakij R, et al: Transcriptional induction of periostin by a sulfatase 2-TGFβ1-SMAD signaling axis mediates tumor angiogenesis in hepatocellular carcinoma. Cancer Res. 77:632–645. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Gao W, Kim H and Ho M: Human monoclonal antibody targeting the heparan sulfate chains of glypican-3 inhibits HGF-mediated migration and motility of hepatocellular carcinoma cells. PLoS One. 10:e01376642015. View Article : Google Scholar : PubMed/NCBI | |
|
Gao H, Li K, Tu H, Pan X, Jiang H, Shi B, Kong J, Wang H, Yang S, Gu J and Li Z: Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma. Clin Cancer Res. 20:6418–6428. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Liu S, Li Y, Chen W, Zheng P, Liu T, He W, Zhang J and Zeng X: Silencing glypican-3 expression induces apoptosis in human hepatocellular carcinoma cells. Biochem Biophys Res Commun. 419:656–661. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Qi XH, Wu D, Cui HX, Ma N, Su J, Wang YT and Jiang YH: Silencing of the glypican-3 gene affects the biological behavior of human hepatocellular carcinoma cells. Mol Med Rep. 10:3177–3184. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Yu D, Dong Z, Yao M, Wu W, Yan M, Yan X, Qiu L, Chen J, Sai W and Yao D: Targeted glypican-3 gene transcription inhibited the proliferation of human hepatoma cells by specific short hairpin RNA. Tumour Biol. 34:661–668. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Yao M, Wang L, Dong Z, Qian Q, Shi Y, Yu D, Wang S, Zheng W and Yao D: Glypican-3 as an emerging molecular target for hepatocellular carcinoma gene therapy. Tumour Biol. 35:5857–5868. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Ikeda M, Ohkawa S, Okusaka T, Mitsunaga S, Kobayashi S, Morizane C, Suzuki I, Yamamoto S and Furuse J: Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma. Cancer Sci. 105:455–462. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Sawada Y, Sakai M, Yoshikawa T, Ofuji K and Nakatsura T: A glypican-3-derived peptide vaccine against hepatocellular carcinoma. Oncoimmunology. 1:1448–1450. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu AX, Gold PJ, El-Khoueiry AB, Abrams TA, Morikawa H, Ohishi N, Ohtomo T and Philip PA: First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 19:920–928. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Huang N, Lin J, Ruan J, Su N, Qing R, Liu F, He B, Lv C, Zheng D and abd Luo R: MiR-219-5p inhibits hepatocellular carcinoma cell proliferation by targeting glypican-3. FEBS Lett. 586:884–891. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Wang K, Kievit FM, Sham JG, Jeon M, Stephen ZR, Bakthavatsalam A, Park JO and Zhang M: Iron-oxide-based nanovector for tumor targeted siRNA delivery in an orthotopic hepatocellular carcinoma xenograft mouse model. Small. 12:477–487. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Hanaoka H, Nakajima T, Sato K, Watanabe R, Phung Y, Gao W, Harada T, Kim I, Paik CH, Choyke PL, et al: Photoimmunotherapy of hepatocellular carcinoma-targeting glypican-3 combined with nanosized albumin-bound paclitaxel. Nanomedicine (Lond). 10:1139–1147. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Li SQ, Lin J, Qi CY, Fu SJ, Xiao WK, Peng BG and Liang LJ: GPC3 DNA vaccine elicits potent cellular antitumor immunity against HCC in mice. Hepatogastroenterology. 61:278–284. 2014.PubMed/NCBI |
